JP2005522521A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522521A5
JP2005522521A5 JP2003585506A JP2003585506A JP2005522521A5 JP 2005522521 A5 JP2005522521 A5 JP 2005522521A5 JP 2003585506 A JP2003585506 A JP 2003585506A JP 2003585506 A JP2003585506 A JP 2003585506A JP 2005522521 A5 JP2005522521 A5 JP 2005522521A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
administering
ferritin
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/011411 external-priority patent/WO2003088748A1/en
Publication of JP2005522521A publication Critical patent/JP2005522521A/ja
Publication of JP2005522521A5 publication Critical patent/JP2005522521A5/ja
Pending legal-status Critical Current

Links

JP2003585506A 2002-04-15 2003-04-15 ヘムオキシゲナーゼ−1およびヘム分解産物の使用法 Pending JP2005522521A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37276202P 2002-04-15 2002-04-15
PCT/US2003/011411 WO2003088748A1 (en) 2002-04-15 2003-04-15 Use of heme oxygenase-1 and products of heme degradation

Publications (2)

Publication Number Publication Date
JP2005522521A JP2005522521A (ja) 2005-07-28
JP2005522521A5 true JP2005522521A5 (cg-RX-API-DMAC7.html) 2006-06-08

Family

ID=29250903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585506A Pending JP2005522521A (ja) 2002-04-15 2003-04-15 ヘムオキシゲナーゼ−1およびヘム分解産物の使用法

Country Status (6)

Country Link
US (2) US8097585B2 (cg-RX-API-DMAC7.html)
EP (1) EP1499186A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005522521A (cg-RX-API-DMAC7.html)
AU (2) AU2003226366A1 (cg-RX-API-DMAC7.html)
CA (1) CA2482260A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003088748A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7238469B2 (en) * 2001-06-21 2007-07-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
KR20040096571A (ko) * 2002-02-13 2004-11-16 베쓰 이스라엘 디코니스 메디칼 센터 인크 혈관 질환을 치료하는 방법
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
ES2546280T3 (es) * 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
CA2485465A1 (en) * 2002-05-17 2003-11-27 Yale University Methods of treating hepatitis
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶-1和血红素降解产物的药学用途
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
US7504243B2 (en) * 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
WO2006054757A1 (ja) * 2004-11-16 2006-05-26 Astellas Pharma Inc. カスパーゼ阻害剤
WO2006132583A1 (en) * 2005-06-07 2006-12-14 Innate Pharmaceuticals Ab Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
WO2008008513A2 (en) * 2006-07-13 2008-01-17 Beth Israel Deaconess Medical Center Inc. Combination treatments
WO2008113134A1 (en) * 2007-03-20 2008-09-25 Garvan Institute Of Medical Research Method of transplantation of a kidney
US20120177601A1 (en) * 2009-07-02 2012-07-12 The Usa As Represented By The Secretary Of The Department Of Veterans Affairs Treatment of hepatitis c virus infections
US8455222B2 (en) 2009-11-04 2013-06-04 Utah State University Biliverdin from a non-animal source
WO2014043647A1 (en) 2012-09-14 2014-03-20 Utah State University Therapeutic compositions and associated methods
US20140112882A1 (en) * 2012-10-08 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Methods to treat pancreatic inflammation and associated lung injury through regulation of pancreatic interleukin-22 expression
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
ES3039332T3 (en) * 2019-05-28 2025-10-20 Previpharma Consulting Gmbh Method for preparing iron-depleted ferritin and use thereof
KR102691510B1 (ko) * 2021-10-14 2024-08-05 건국대학교 산학협력단 Heme oxygenase-1(HO-1) 또는 HO-1 발현 유도제를 포함하는 A형 간염 바이러스 예방 또는 치료용 약학적 조성물

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
JPS5381611A (en) 1976-12-28 1978-07-19 Kimihiko Okazaki Hepatic medicine
US4264739A (en) 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US4979939A (en) 1984-05-14 1990-12-25 Surgical Systems & Instruments, Inc. Atherectomy system with a guide wire
US5084380A (en) 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
CA2155947C (en) 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
WO1994022482A1 (en) 1993-03-26 1994-10-13 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5763431A (en) 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
CA2132690A1 (en) 1994-09-22 1996-03-23 Dean Willis Control and modulation of inflammatory response in humans in need of such control and modulation
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
US5664563A (en) 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
DE69632402T2 (de) 1995-06-30 2005-05-19 Zymogenetics, Inc., Seattle 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste
DE19535781C2 (de) 1995-09-26 1999-11-11 Fraunhofer Ges Forschung Vorrichtung zur aktiven Strömungsunterstützung von Körperflüssigkeiten
JP2000510448A (ja) 1996-04-05 2000-08-15 ザ ジェネラル ホスピタル コーポレーション 異常ヘモグロビン症の治療
US6069132A (en) 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
DE69733081T2 (de) 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
WO1998008523A1 (de) 1996-08-27 1998-03-05 Messer Griesheim Gmbh Wasserstoffhaltiges medikament
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
EP0951292B1 (en) 1996-09-27 2007-04-04 The Trustees of Columbia University in the City of New York Treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6316403B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6436365B2 (en) 1997-09-23 2002-08-20 Schering Aktiengesellschaft Process for therapeutic treatment of proliferative diseases
US6251418B1 (en) 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
TR200101500T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
US6450989B2 (en) 1998-04-27 2002-09-17 Artemis Medical, Inc. Dilating and support apparatus with disease inhibitors and methods for use
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
JP2003500335A (ja) 1998-12-17 2003-01-07 サングスタット メディカル コーポレイション ヘムオキシゲナーゼ活性の調節による移植片の生存を強化する方法
US20050250688A1 (en) 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
EP1181032A4 (en) * 1999-04-14 2004-08-25 Breonics Inc BLOOD METABOLIC SUPPORT SYSTEM FOR AN ORGAN OR TISSUE
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6508784B1 (en) 2000-05-19 2003-01-21 Yan-Ho Shu Balloon catheter having adjustable centering capabilities and methods thereof
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
BR0208012A (pt) 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
CN1507348A (zh) 2001-03-30 2004-06-23 ɣ����ҽҩ��˾ 用于治疗血管性、炎性和免疫疾病的一氧化碳生成性组合物
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
WO2002096387A1 (en) 2001-05-25 2002-12-05 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
US7238469B2 (en) 2001-06-21 2007-07-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
EP2319518A1 (en) 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
KR20040096571A (ko) * 2002-02-13 2004-11-16 베쓰 이스라엘 디코니스 메디칼 센터 인크 혈관 질환을 치료하는 방법
ES2546280T3 (es) 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
EP1499328B1 (en) 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
CA2485465A1 (en) 2002-05-17 2003-11-27 Yale University Methods of treating hepatitis
CA2487413A1 (en) 2002-06-05 2003-12-18 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
CN1674942A (zh) 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶-1和血红素降解产物的药学用途
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
AU2003283982A1 (en) 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
US7504243B2 (en) * 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin

Similar Documents

Publication Publication Date Title
JP2020513745A5 (cg-RX-API-DMAC7.html)
JP2020511414A5 (cg-RX-API-DMAC7.html)
JP2011507933A5 (cg-RX-API-DMAC7.html)
JP2009537498A5 (cg-RX-API-DMAC7.html)
JP2013509411A5 (cg-RX-API-DMAC7.html)
JP2005532351A5 (cg-RX-API-DMAC7.html)
JP2009511482A5 (cg-RX-API-DMAC7.html)
WO2007012254A1 (en) Rhein conjugates, preparation method thereof and their uses in producing medicines for treating diabetic nephrosis, intestinal adhesion and osteoarthritis
JP2544868B2 (ja) 呼吸器官系疾患治療用薬剤
CN103179967B (zh) 抗肿瘤药物组合物
CN110354270A (zh) 一种青蒿琥酯聚乙二醇衍生物及其制备方法和应用、一种防治肺炎的药物
Jin et al. Intraduodenal and intrajejunal administration of the herbal medicine, dai-kenchu-tou, stimulates small intestinal motility via cholinergic receptors in conscious dogs
Olivares-Rubio et al. Role of epoxyeicosatrienoic acids in the lung
JP2024527023A5 (cg-RX-API-DMAC7.html)
CN108283643A (zh) 一种噻嗪二酮类化合物在制备预防或治疗类风湿性关节炎的药物中的应用
WO2011088715A1 (zh) 芍药内酯苷的抗帕金森症用途
WO2010081266A1 (zh) 延胡索乙素的新用途
TWI333857B (en) Intranasal pharmaceutical composition for treating non-viral induced airway inflammation or allergic diseases and uses thereof
JP7182807B2 (ja) 14-デオキシ-11,12-デヒドロ-8,12-エポキシまたは7,8-エン-アンドログラフォライドおよびその15位置換誘導体と用途
CN102772651B (zh) 治疗风燥伤肺型咳嗽的中药组合物及其制备方法
CN120392742A (zh) Act001在制备治疗脊髓损伤的药物中的应用
WO2021024906A1 (ja) 短鎖脂肪酸エステルを担持する親水-疎水性共重合体
CN113413402A (zh) 梅花草提取物在制备治疗幽门螺杆菌感染疾病药物中的应用
CN104800204B (zh) 桑辛素抗肿瘤用途
CN106362147A (zh) No供体型二氧化钛衍生物的药物组合物的制备及应用